Saurabh Saha - 01 Jul 2022 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role
Chief Executive Officer, Director
Signature
/s/ Marella Thorell, attorney-in-fact
Issuer symbol
CNTA
Transactions as of
01 Jul 2022
Net transactions value
$0
Form type
4
Filing time
06 Jul 2022, 18:16:07 UTC
Previous filing
27 Jun 2022
Next filing
04 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CNTA Ordinary Shares Award $0 +750,000 $0.000000 750,000 01 Jul 2022 Direct F1, F2
holding CNTA Ordinary Shares 38,000 01 Jul 2022 By trust F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 The shares reported in this transaction represent Restricted Share Units ("RSUs") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in 10 equal quarterly instalments with the first such quarterly vesting being on September 30, 2022.
F3 These shares are held directly in a trust, for which the reporting person and his spouse serve as trustees.